Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Target volume delineation.
- Who it may be relevant to
- Registry conditions: Spinal Tumor. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.
Detailed description
The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors. This is a bidirectional cohort study planned to enroll approximately 500 patients with metastatic spinal tumors. Patients are divided into two groups according to the target delineation method. Group 1：The target bolume only includes local tumor. Group 2：The target bolume includes local tumor and adjacent vertebral area.
Interventions
- Radiation Target volume delineation
Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.
Primary outcome measures
- Disease Control Rate（DCR） [Time frame: 2 years]
- Pain relief rate [Time frame: 3 months]
Secondary outcome measures (1)
- Incidence of side effects [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy;
- Patients with sufficent pre-treatment imaging data
- Patients who can cooperate with imaging review and follow-up after radiotherapy.
Exclusion criteria
- Patients with an expected survival of less than 3 months;
- Patients with second-course radiotherapy;
- Patients with physical conditions that cannot tolerate stereotactic radiotherapy;
- Patients with extensive spinal metastasis and no local therapeutic value
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North — Beijing
Identifiers
NCT: NCT06587022 · ST-SBRT